Background Tocilizumab, an interleukin-6 receptor antagonist, has been proposed as an adjunctive treatment for severe coronavirus disease 2019 (COVID-19) to mitigate hyperinflammation. While multiple trials have been published, uncertainty persists regarding its overall efficacy and consistency across clinical contexts. Methods The present systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines (PROSPERO CRD420251089853). PubMed/MEDLINE, Scopus, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov were searched through mid-2025. Only randomized controlled trials enrolling hospitalized adults with COVID-19 were included. The primary outcome was all-cause mortality; secondary outcomes were intensive care unit (ICU) admission, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). Subgroup analyses were prespecified according to dose category (≤ 400 mg vs. > 400 mg), re-dosing schedule, clinical setting (ICU, non-ICU ward, or mixed), and baseline ventilatory exclusions. Risk of bias was assessed using RoB 2.0 and certainty of evidence by GRADE. Results Twenty randomized trials comprising twenty-three reports were eligible for quantitative synthesis. Tocilizumab significantly reduced all-cause mortality compared with standard of care or placebo (risk ratio [RR] = 0.89; 95% confidence interval [CI] = 0.83–0.96; p < 0.001; I² = 42.8%). No significant effects were observed for ICU admission (RR = 0.96; 95% CI = 0.87–1.06; I² = 11.3%) or NIV (RR = 0.88; 95% CI = 0.77–1.02; I² = 0.0%), whereas IMV showed a borderline reduction (RR = 0.78; 95% CI = 0.61–1.00; p = 0.05; I² = 56.3%). Egger’s tests indicated no small-study bias across outcomes (all p > 0.25). Subgroup analyses revealed no effect modification by dose category, setting, or baseline ventilation status, although single-dose regimens were associated with more favorable estimates. The certainty of evidence was rated low to moderate for mortality and low to very low for ventilation outcomes. Conclusions Tocilizumab confers a modest but statistically significant survival benefit in hospitalized adults with COVID-19, independent of care setting and concomitant corticosteroid use, while effects on escalation outcomes remain uncertain. These findings, derived exclusively from randomized evidence including major platform trials, strengthen current guideline recommendations supporting early single-dose administration in patients with systemic inflammation and progressive respiratory compromise.

Tocilizumab and COVID-19 Outcomes: An Updated Meta-Analysis of Randomized Controlled Trials

期刊论文
发表日期：

2026年3月26日

查看全文

Babak Ghadirzadeh,
Maziar Afshar,
Yousef Moradi

摘要

Background

Tocilizumab, an interleukin-6 receptor antagonist, has been proposed as an adjunctive treatment for severe coronavirus disease 2019 (COVID-19) to mitigate hyperinflammation. While multiple trials have been published, uncertainty persists regarding its overall efficacy and consistency across clinical contexts.

Methods

The present systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines (PROSPERO CRD420251089853). PubMed/MEDLINE, Scopus, Embase, Web of Science, Cochrane Library, and ClinicalTrials.gov were searched through mid-2025. Only randomized controlled trials enrolling hospitalized adults with COVID-19 were included. The primary outcome was all-cause mortality; secondary outcomes were intensive care unit (ICU) admission, non-invasive ventilation (NIV), and invasive mechanical ventilation (IMV). Subgroup analyses were prespecified according to dose category (≤ 400 mg vs. > 400 mg), re-dosing schedule, clinical setting (ICU, non-ICU ward, or mixed), and baseline ventilatory exclusions. Risk of bias was assessed using RoB 2.0 and certainty of evidence by GRADE.

Results

Twenty randomized trials comprising twenty-three reports were eligible for quantitative synthesis. Tocilizumab significantly reduced all-cause mortality compared with standard of care or placebo (risk ratio [RR] = 0.89; 95% confidence interval [CI] = 0.83–0.96; p < 0.001; I² = 42.8%). No significant effects were observed for ICU admission (RR = 0.96; 95% CI = 0.87–1.06; I² = 11.3%) or NIV (RR = 0.88; 95% CI = 0.77–1.02; I² = 0.0%), whereas IMV showed a borderline reduction (RR = 0.78; 95% CI = 0.61–1.00; p = 0.05; I² = 56.3%). Egger’s tests indicated no small-study bias across outcomes (all p > 0.25). Subgroup analyses revealed no effect modification by dose category, setting, or baseline ventilation status, although single-dose regimens were associated with more favorable estimates. The certainty of evidence was rated low to moderate for mortality and low to very low for ventilation outcomes.

Conclusions

Tocilizumab confers a modest but statistically significant survival benefit in hospitalized adults with COVID-19, independent of care setting and concomitant corticosteroid use, while effects on escalation outcomes remain uncertain. These findings, derived exclusively from randomized evidence including major platform trials, strengthen current guideline recommendations supporting early single-dose administration in patients with systemic inflammation and progressive respiratory compromise.